FDA Reorganizes Regulatory Affairs Office to Respond to Drug Industry Globalization
The FDA is planning to reorganize its Office of Regulatory Affairs (ORA), including creating new offices and reorganizing others, as it takes steps to dissolve cumbersome domestic and international distinctions and to keep up with increasingly global operations.
The restructuring will also better position the ORA to address new legislative authorities included in the FDA Safety and Innovation Act (FDASIA), signed into law this summer, which boosts the FDA’s supply chain oversight and inspection authority while allowing for risk-based approaches to both — major changes that call for “new strategies” and enhanced coordination across the office, according to an agency fact sheet on the ORA reorganization.
Overseeing the reorganization will be a new Office of Operations. The current Assistant Commissioner for Field Operations, Roberta Wagner, will head that office as Assistant Commissioner for Operations.
Also in transition is current Associate Commissioner for Regulatory Affairs Dara Corrigan who will become the director of the FDA’s European office in Brussels and Senior Adviser for Global Operations, FDA spokeswoman Carla Daniels said. Melinda Plaisier, a regional food and drug director in Chicago, will assume Corrigan’s duties in an acting role.
Drug Industry Daily offer executives daily electronic briefing of what's happening on Capitol Hill, the FDA, FTC, HHS, NIH and other key agencies and decision making bodies that affect the pharmaceutical industry.
It’s the fastest, most reliable way to make sure you're an industry expert, so get up to speed and subscribe to our daily publication today!
Come for this valuable opportunity to hear FDA officials discuss regulatory plans and objectives — and ask questions you need answered; learn from device industry experts, consultants and other experts with actionable tips and strategies you can take straight back to the office; and network with other professionals who understand your challenges; share war stories and insights over a drink. Register Today.Read More
The FDA's new enforcement plan makes one thing clear: Developing a successful CAPA program has never been more important. But creating an FDA-proof CAPA isn’t easy. If only you could pick the brain of someone who is coping successfully with CAPA — the best and the brightest, an industry leader who has devised programs, procedures and solutions that have put companies out in front with the FDA. Well, you can. Register today.Read More
The FDA’s cadre of freshly trained inspectors — many of whom come directly from industry — and increased focus on specialized inspections are making it harder than ever to predict the outcome of your next FDA inspection. Unless, of course, you have Surviving an FDA Inspection at your fingertips. If you could spend less than $400 to get your drug manufacturing facility fully prepared to face a tough inspection by the FDA, would you even hesitate? ... Of course not!